EMEA-000645-PIP04-20

Table of contents

Key facts

Invented name
Entyvio
Active substance
vedolizumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0186/2021
PIP number
EMEA-000645-PIP04-20
Pharmaceutical form(s)
  • Powder for concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of pouchitis
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Takeda Pharma A/S

E-mail: paediatrics@tgrd.com
Tel. +44 2031168000

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating